Thomas Clozel

Thomas is the CEO and Co-Founder at Owkin, leading medical research and business intelligence. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris. Thomas is also a former member of Ari Melnick’s lab at the Weill Cornell Medical College where he co-led several projects focused on prediction of resistance to chemotherapy in B-cell lymphoma.

Abstract – The medicine of tomorrow

The medicine of tomorrow. Medicine today is booming in multiple fields. However, research is still slow on multiple fronts, many diseases are still unmet needs, precision medicine remains an exception, and pharmaceutical companies’ efficiency is not building up at high pace. But the medicine of tomorrow is at our doors, fed by the progress of quantum computers and data science, breaking silos of research and competition, and energized by new flux of breakthroughs and data. What will the medicine of tomorrow look like in that regard? What can we hope for patients and caregivers?